HeartRhythm

DECEMBER 31, 2024

Curtain etal1 performed an analysis of the VALIANT (Valsartan in Acute Myocardial Infarction) and PARADISE-MI (Prospective ARNi vs ACE Inhibitor Trial to Determine Superiority in Reducing Heart Failure Events After MI) trials to evaluate whether risk of sudden cardiac arrest (SCA) following acute myocardial infarction (MI) has changed over time.

Cardiac Arrest 79

Cardiac Arrest ACE Inhibitor Myocardial Infarction Heart Failure 79

JAMA Cardiology

AUGUST 6, 2024

This secondary analysis of the Valsartan in Acute Myocardial Infarction (VALIANT) and Prospective ARNi vs ACE Inhibitor Trial to Determine Superiority in Reducing Heart Failure Events After MI (PARADISE-MI) randomized clinical trials investigates the changes over time in sudden death rate after myocardial infarction and the characteristics of people (..)

Myocardial Infarction 88

Myocardial Infarction ACE Inhibitor Heart Failure 88

American College of Cardiology

MARCH 6, 2024

The goal of the PARADISE-MI trial was to assess the efficacy and safety of sacubitril/valsartan compared with ramipril in a contemporary acute myocardial infarction (AMI) population.

ACE Inhibitor 44

ACE Inhibitor Myocardial Infarction Heart Failure Article 44

European Journal of Heart Failure

NOVEMBER 29, 2023

Sacubitril/valsartan and a mineralocorticoid receptor anatogonist (MRA) can be initiated safely and used simultaneously in post-myocardial infarction complicated by left ventricular (LV) dysfunction, congestion or both – Insight from the PARADISE MI trial. Safety was defined as symptomatic hypotension, hyperkalaemia >5.5 mmol/L,

Myocardial Infarction 40

Myocardial Infarction ACE Inhibitor Heart Failure Pulmonary 40

DAIC

APRIL 6, 2024

The EMPACT-MI trial was designed to determine whether SGLT-2 inhibitors could safely help to prevent heart failure and reduce mortality in people with a high risk of heart failure following a heart attack. The study enrolled 6,522 people treated for acute myocardial infarction at 451 centers in 22 countries.

Heart attacks 98

Heart attacks Heart Attack Heart Failure Outpatient 98

Heart BMJ

JANUARY 10, 2024

The primary outcome was major adverse cardiovascular events (MACEs; all-cause mortality, stroke or myocardial infarction). Time-updated adjusted Cox regression models were used to compare patients with and without RAS inhibitors. Both treatment with ACE inhibitors (aHR 0.89 (95% CI 0.82 to 0.86), p<0.001).

Aortic valve 40

Aortic valve Aortic ACE Inhibitor Stenosis 40

DAIC

APRIL 6, 2024

The EMPACT-MI trial was designed to determine whether SGLT-2 inhibitors could safely help to prevent heart failure and reduce mortality in people with a high risk of heart failure following a heart attack. The study enrolled 6,522 people treated for acute myocardial infarction at 451 centers in 22 countries. 24 conference.

Heart Attack 81

Heart Attack Heart attacks Heart Failure Outcomes 81